Biopharmaceutical

Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference

Retrieved on: 
Friday, February 28, 2020
Life sciences, Articles, Biotechnology, Nektar Therapeutics, Specialty drugs, Banjalučka Pivara, Biopharmaceutical

SAN FRANCISCO, Feb. 28, 2020 /PRNewswire/ --Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time.

Key Points: 
  • SAN FRANCISCO, Feb. 28, 2020 /PRNewswire/ --Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time.
  • The presentation will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website: http://ir.nektar.com/events-and-presentations/events .This Webcast will be available for replay until April 3, 2020.
  • Nektar Therapeutics is a biopharmaceutical company with a robust, wholly-owned R&D pipeline of investigational medicines in oncology and immunology as well as a portfolio of approved partnered medicines.
  • Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com .

CytRx Corporation Clarifies Certain Prior Disclosures Regarding its Relationship with Orphazyme A/S

Retrieved on: 
Friday, February 28, 2020
Life sciences, Articles, Biotechnology, CytRx, Arimoclomol, OTC Markets Group, Neurodegeneration, Biopharmaceutical

LOS ANGELES, Feb. 28, 2020 /PRNewswire/ --CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today clarified certain prior disclosures regarding its relationship with Orphazyme A/S.

Key Points: 
  • LOS ANGELES, Feb. 28, 2020 /PRNewswire/ --CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today clarified certain prior disclosures regarding its relationship with Orphazyme A/S.
  • CytRx has correctly described its relationship with Orphazyme in its reports filed with the SEC, but inadvertently characterized Orphazyme as a licensee of arimoclomol rather than a purchaser in certain prior press releases.
  • CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases.
  • All forward-looking statements are based upon information available to CytRx on the date the statements are first published.

Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market

Retrieved on: 
Friday, February 28, 2020
Life sciences, Articles, Biotechnology, U.S. Securities and Exchange Commission, Shelf registration, Prospectus, Registration statement, Biopharmaceutical

The gross proceeds of the offering will be $16,005,000 before deducting fees and other estimated offering expenses.

Key Points: 
  • The gross proceeds of the offering will be $16,005,000 before deducting fees and other estimated offering expenses.
  • This offering was made pursuant to an effective shelf registration statement on Form S-3 (File No.
  • A prospectus supplement relating to the shares of common stock will be filed by Tonix with the SEC.
  • Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing small molecules and biologics to treat pain, addiction and psychiatric conditions.

Protein Sequencing Industry Projected to Reach $9.9 Billion by 2026 - Key Insights, Opportunities & Challenges; Profiles of Key Players

Retrieved on: 
Friday, February 28, 2020
Branches of biology, Natural sciences, Biology, Molecular biology, Proteomics, Biotechnology, Protein methods, Sequencing, Edman degradation, Protein sequencing, Edman, Biopharmaceutical

According to the report, the global protein sequencing market is expected to reach $9,926.7 million by 2026, registering a CAGR of 7.8% from 2019 to 2026, in terms of value.

Key Points: 
  • According to the report, the global protein sequencing market is expected to reach $9,926.7 million by 2026, registering a CAGR of 7.8% from 2019 to 2026, in terms of value.
  • Surge in focus toward target-based drug development by pharmaceutical and biotechnology companies is the major factor anticipated to drive the protein sequencing market growth.
  • Based on technology, the Edman degradation segment accounted for 58% share in the protein sequencing market in 2018.
  • Based on protein sequencing market analysis, by application, the biopharmaceuticals segment dominated the protein sequencing market in 2018 and is anticipated to maintain its dominance during the forecast period.

Molecular Templates to Present at Three March Investor Conferences

Retrieved on: 
Friday, February 28, 2020
Life sciences, Articles, Biotechnology, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Cowen Inc.

AUSTIN, Texas, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, Molecular Templates or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the companys proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that management will present a corporate overview at the Cowen & Company 40th Annual Health Care Conference, the Barclays Global Healthcare Conference, and the Oppenheimer 30th Annual Healthcare Conference.

Key Points: 
  • AUSTIN, Texas, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, Molecular Templates or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the companys proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that management will present a corporate overview at the Cowen & Company 40th Annual Health Care Conference, the Barclays Global Healthcare Conference, and the Oppenheimer 30th Annual Healthcare Conference.

Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference

Retrieved on: 
Friday, February 28, 2020
Life sciences, Articles, Pharmaceutical industry, Biotechnology, Specialty drugs, Medication, Biopharmaceutical, Integrin

WALTHAM, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, todayannounced that Praveen Tipirneni, M.D., president and chief executive officer of Morphic Therapeutic, is scheduled to present at the 40th Annual Cowen Health Care Conference at 8:00 AM ET on Wednesday, March 4, 2020.

Key Points: 
  • WALTHAM, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, todayannounced that Praveen Tipirneni, M.D., president and chief executive officer of Morphic Therapeutic, is scheduled to present at the 40th Annual Cowen Health Care Conference at 8:00 AM ET on Wednesday, March 4, 2020.
  • Dr. Tipirneni will provide an update on the companys progress across its portfolio of oral small molecule integrin inhibitors.
  • A live webcast of the presentation will be available on the Investors section of Morphics website at https://www.morphictx.com .
  • Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.

Harbour BioMed Announces U.S. FDA Approval of IND for Its Next Generation anti-CTLA-4 Antibody, HBM4003, to Treat Cancer

Retrieved on: 
Friday, February 28, 2020
Oncology, Health, FDA, Clinical trials, Pharmaceutical, Biotechnology, Life sciences, Articles, Health, Cancer immunotherapy, Investigational New Drug, Biopharmaceutical

Harbour BioMed (HBM) today announced U.S. Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application to begin clinical studies with HBM4003, its next generation anti-CTLA-4 antibody for the treatment of cancer.

Key Points: 
  • Harbour BioMed (HBM) today announced U.S. Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application to begin clinical studies with HBM4003, its next generation anti-CTLA-4 antibody for the treatment of cancer.
  • The trial will evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of HBM4003 as a single agent in subjects with advanced solid tumors.
  • The IND approval is an important next step in our global program to develop this exciting molecule, said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.
  • Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases.

Regen Suppliers Now Offering 20% Discount On Biologics Orders to New Customers

Retrieved on: 
Friday, February 28, 2020
Life sciences, Biotechnology, Articles, Stem cells, Embryology, Regeneration, Umbilical cord, Umbilical, Biopharmaceutical, Regen

SCOTTSDALE, Ariz., Feb. 28, 2020 /PRNewswire-PRWeb/ -- Regen Suppliers is now offering first time customers a 20% discount on initial biologics orders.

Key Points: 
  • SCOTTSDALE, Ariz., Feb. 28, 2020 /PRNewswire-PRWeb/ -- Regen Suppliers is now offering first time customers a 20% discount on initial biologics orders.
  • Regen Suppliers offers an extensive variety of regenerative therapy products, including amniotic and umbilical tissue, Exosome Biologics, PRP kits, adipose kits, PDO thread lifts and more.
  • For example, Regen Suppliers has its own line for umbilical cord tissue and Exosome Biologics.
  • In addition, Regen Suppliers has also teamed up with R3 Medical Training for provider's regenerative medicine training courses .

Immunomedics Appoints Robert W. Azelby to Board of Directors

Retrieved on: 
Thursday, February 27, 2020
Life sciences, Articles, Biotechnology, Immunomedics, Alder Biopharmaceuticals, Lundbeck, Antibody-drug conjugate, Biopharmaceutical

MORRIS PLAINS, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (Immunomedics or the Company), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADCs), today announced the appointment of Robert W. Azelby to the Companys board of directors.

Key Points: 
  • MORRIS PLAINS, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (Immunomedics or the Company), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADCs), today announced the appointment of Robert W. Azelby to the Companys board of directors.
  • I am excited to join Immunomedics at an inflection point as the Company is preparing for its first potential commercial launch in its history, said Mr. Azelby.
  • Mr. Azelby was recently the president and chief executive officer, and a member of the board of directors, of Alder BioPharmaceuticals, Inc., which was acquired by H. Lundbeck A/S in October 2019.
  • Mr. Azelby currently serves on the board of directors of Clovis Oncology, Inc. and he previously served on the board of directors of Cascadian Therapeutics, Inc. Mr. Azelby holds a B.A.

Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights

Retrieved on: 
Thursday, February 27, 2020
Life sciences, Biotechnology, Biology, eIF2, Gene expression, Molecular biology, Protein biosynthesis, Denali, Biopharmaceutical

First-in-human dosing of EIF2B activator program (DNL343) - In February 2020, Denali commenced dosing of its small molecule activator of EIF2B, DNL343, in healthy volunteers.

Key Points: 
  • First-in-human dosing of EIF2B activator program (DNL343) - In February 2020, Denali commenced dosing of its small molecule activator of EIF2B, DNL343, in healthy volunteers.
  • For the quarter ended December 31, 2019, Denali reported a net loss of $54.0million compared with net income of $77.5million for the quarter ended December 31, 2018.
  • Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases.
  • The forward-looking statements in this press release are based on information available to Denali as of the date hereof.